1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea (BioDeep_00000176281)

   

human metabolite blood metabolite


代谢物信息卡片


3-cyclopropyl-1-(5-{6-[(morpholin-4-yl)methyl]-1H-1,3-benzodiazol-2-yl}-1H-pyrazol-4-yl)urea

化学式: C19H23N7O2 (381.1913)
中文名称: AT9283
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5
InChI: InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor

同义名列表

5 个代谢物同义名

3-cyclopropyl-1-(5-{6-[(morpholin-4-yl)methyl]-1H-1,3-benzodiazol-2-yl}-1H-pyrazol-4-yl)urea; 3-cyclopropyl-1-{3-[5-(morpholin-4-ylmethyl)-3H-1,3-benzodiazol-2-yl]-2H-pyrazol-4-yl}urea; 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea; 1-Cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea; AT9283



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Janna K Duong, Melanie J Griffin, Darren Hargrave, Josef Vormoor, David Edwards, Alan V Boddy. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. British journal of clinical pharmacology. 2017 08; 83(8):1713-1722. doi: 10.1111/bcp.13260. [PMID: 28177130]
  • Lucas Moreno, Lynley V Marshall, Andrew D J Pearson, Bruce Morland, Martin Elliott, Quentin Campbell-Hewson, Guy Makin, Sarah E R Halford, Gary Acton, Philip Ross, Shamim Kazmi-Stokes, Victoria Lock, Ana Rodriguez, John F Lyons, Alan V Boddy, Melanie J Griffin, Murray Yule, Darren Hargrave. A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan; 21(2):267-73. doi: 10.1158/1078-0432.ccr-14-1592. [PMID: 25370467]
  • H-T Arkenau, R Plummer, L R Molife, D Olmos, T A Yap, M Squires, S Lewis, V Lock, M Yule, J Lyons, H Calvert, I Judson. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 May; 23(5):1307-1313. doi: 10.1093/annonc/mdr451. [PMID: 22015452]
  • Jennifer E Podesta, Richard Sugar, Matt Squires, Spiros Linardopoulos, Andrew D J Pearson, Andrew S Moore. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia research. 2011 Sep; 35(9):1273-5. doi: 10.1016/j.leukres.2011.05.022. [PMID: 21665275]